CIK 0001625101 · Non-accelerated filer<br>Smaller reporting company
PULSE BIOSCIENCES, INC.
Sign in to watch- Ticker
- PLSE
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 465696597
- Phone
- 510-906-4600
- Business address
- 3957 POINT EDEN WAY, HAYWARD, CA, 94545
- Former names
- Electroblate, Inc.
- Open-market buys, last 90 days
- $199,937
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$199,937. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-09 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 405,000 | ||
| 2026-02-05 | Sainz Maria Director | Grant or award · Stock Option (right to buy) | +3,104 | 3,104 | ||
| 2026-01-08 | Sainz Maria Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2025-10-02 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 | +4,600 | $1.53 | $7K | 47,898 |
| 2025-10-02 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 | −4,600 | $18.53 | $85K | 43,298 |
| 2025-10-02 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −4,600 | 425,000 | ||
| 2025-09-19 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 | +400 | $1.53 | $612 | 43,698 |
| 2025-09-19 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 | −400 | $18.48 | $7K | 43,298 |
| 2025-09-19 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −400 | 429,600 | ||
| 2025-09-18 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise 10b5-1 | +20,000 | $1.53 | $31K | 63,298 |
| 2025-09-18 | Danahy Kevin Patrick Chief Commercial Officer | Sale 10b5-1 | −20,000 | $18.49 | $370K | 43,298 |
| 2025-09-18 | Danahy Kevin Patrick Chief Commercial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 430,000 | ||
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 | +20,000 | $4.00 | $80K | 142,872 |
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Sale 10b5-1 | −20,000 | $16.21 | $324K | 122,872 |
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 | +61,534 | $4.00 | $246K | 184,406 |
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 | +100,000 | $4.00 | $400K | 284,406 |
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −20,000 | 61,534 | ||
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −61,534 | 0 | ||
| 2025-09-17 | UECKER DARRIN Chief Technology Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −100,000 | 0 | ||
| 2025-09-16 | UECKER DARRIN Chief Technology Officer | Option exercise 10b5-1 | +25,000 | $4.00 | $100K | 147,872 |
Page 3 of 15 · 292 trades